SCHEMBL4359782

SCHEMBL4359782

O=C1N=C(N2CCOCC2)SC1=Cc1cccc(OCc2ccccc2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.57
MAPT P10636 4/20 0.57
KDM4E B2RXH2 1/20 0.57
GAA P10253 1/20 0.57
KMT2A Q03164 4/20 0.57
MEN1 O00255 3/20 0.57
NPC1 O15118 2/20 0.55
RAB9A P51151 2/20 0.55
CYP1A2 P05177 2/20 0.55
CYP2C19 P33261 2/20 0.55
MMP13 P45452 1/20 0.53
ADAMTS5 Q9UNA0 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.52
HCRTR1 O43613 1/20 0.52
HPGD P15428 1/20 0.52
CNR2 P34972 2/20 0.52
GPR18 Q14330 2/20 0.52
GRIN1 Q05586 3/20 0.51
GRIN2B Q13224 3/20 0.51
HTT P42858 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4359781 1.00 ALDH1A1 (0.57) ALDH1A1MAPTKDM4EGAAKMT2A
SCHEMBL4358719 0.89 MAPT (0.68) ALDH1A1MAPTKDM4EGAAKMT2A
SCHEMBL4358722 0.89 MAPT (0.68) ALDH1A1MAPTKDM4EGAAKMT2A
SCHEMBL4350546 0.87 KMT2A (0.62) ALDH1A1MAPTKDM4EGAAKMT2A
SCHEMBL4350550 0.87 KMT2A (0.62) ALDH1A1MAPTKDM4EGAAKMT2A
SCHEMBL4350336 0.86 MAPT (0.57) ALDH1A1MAPTKDM4EGAAKMT2A
SCHEMBL4350333 0.86 MAPT (0.57) ALDH1A1MAPTKDM4EGAAKMT2A
SCHEMBL4364812 0.83 MEN1 (0.62) ALDH1A1MAPTKDM4EGAAKMT2A
SCHEMBL4350802 0.83 MEN1 (0.62) ALDH1A1MAPTKDM4EGAAKMT2A
SCHEMBL4364816 0.83 MEN1 (0.62) ALDH1A1MAPTKDM4EGAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP claimed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US claimed
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP disclosed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US disclosed
EP-1890695-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2008-02-27 EP disclosed
WO-2006122777-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs ABCB1, ABCG2, SLC5A2 ALDH1A1 284/4885MAPT 1470/4885KDM4E 3224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.